Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
[25] Systematic review	Adults and children with acute asthma 3 RCTs in this analysis	Proportion of people with mild to moderate adverse event timeframe unclear 24/106 (23%) with adding nebulised magnesium sulfate to beta2 agonists 27/103 (26%) with beta2 agonists alone	RD –0.03 95% CI –0.14 to +0.08 P = 0.62		Not significant
[25] Systematic review	Adults and children with acute asthma 4 RCTs in this analysis	Proportion of people with serious adverse event timeframe unclear 0/115 with adding nebulised magnesium sulfate to beta2 agonists 0/108 with beta2 agonists alone	RD 0.00 95% CI –0.03 to +0.03 P = 1.0		Not significant